The blood screening market size was exhibited at USD 3.65 billion in 2024 and is projected to hit around USD 10.74 billion by 2034, growing at a CAGR of 11.4% during the forecast period 2024 to 2034.
| Report Coverage | Details |
| Market Size in 2025 | USD 4.07 Billion |
| Market Size by 2034 | USD 10.74 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 11.4% |
| Base Year | 2024 |
| Forecast Period | 2024-2033 |
| Segments Covered | Technology, Product, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America, Europe, Asia Pacific, Latin America, MEA |
| Key Companies Profiled | Abbott; Danaher Corporation (Beckman Coulter); Becton Dickinson and Company; Bio-Rad Laboratories, Inc.; Hoffman-La Roche Ltd.; Grifols, S.A.; Ortho-Clinical Diagnostics, Inc.; Siemens Healthcare GmbH; Thermo Fisher Scientific, Inc.; SOFINA s.a (Biomerieux). |
This growth is attributed to the increasing number of blood donations worldwide is a primary catalyst, necessitating rigorous screening to ensure safety and detect transfusion-transmissible infections. In addition, technological advancements, particularly in automation and molecular platforms, enhance screening efficiency and accuracy. Furthermore, the rising prevalence of infectious diseases and government initiatives promoting blood safety further contribute to market expansion, alongside growing awareness among the public regarding the importance of safe blood transfusions.
Blood screening is a crucial medical procedure that analyzes blood samples to identify various health conditions and abnormalities. This diagnostic approach provides essential insights into an individual's overall well-being, facilitating early detection, prevention, and management of diseases. It involves assessing blood cell counts, detecting infectious agents such as viruses and bacteria, and measuring chemical levels such as cholesterol and glucose. The importance of blood screening lies in its ability to help healthcare providers identify potential health issues before symptoms arise, making it vital for diagnosing conditions such as anemia, diabetes, infections, and cardiovascular diseases.
Continuous technological advancements enhance the accuracy and efficiency of screening methods while increasing awareness about the significance of early disease detection promotes preventive healthcare practices. The aging population is another factor, as the rising prevalence of diseases requiring blood screening drives demand.
Furthermore, rising healthcare expenditures globally facilitate the adoption of advanced technologies and services in blood screening. These interconnected factors collectively contribute to the ongoing growth and evolution of the blood screening market, emphasizing its significance in proactive healthcare strategies aimed at improving patient outcomes and overall public health.
Nucleic acid amplification tests (NAT) dominated the market and accounted for the largest revenue share of 41.2% in 2024 attributed to the increasing prevalence of infectious diseases, such as HIV and hepatitis, necessitating accurate and rapid testing methods that NAATs provide. These tests offer high sensitivity and specificity, enabling the detection of low viral loads that traditional methods may miss. Furthermore, the rising demand for early diagnosis and monitoring of diseases further drives the adoption of NAATs. Technological advancements in amplification techniques also enhance the efficiency and speed of these tests, making them more accessible in clinical settings.
Next Generation Sequencing (NGS) is expected to grow at a CAGR of 16.5% over the forecast period. The technology has revolutionized genomic analysis by significantly reducing sequencing costs while improving accuracy. In addition, NGS enables comprehensive profiling of genetic mutations, which is crucial for personalized medicine and targeted therapies. Furthermore, its ability to process multiple samples simultaneously enhances throughput in laboratories, making it an attractive option for healthcare providers. The continuous evolution of NGS technologies ensures their relevance in various applications, including early disease detection and monitoring, thus propelling market growth.
Reagents led the market and accounted for the largest revenue share of 74.0% in 2024. Reagents are essential components in diagnostic tests, providing the necessary chemical, biological, or immunological substances to elicit specific reactions for accurate results. In addition, the increasing demand for high specificity and accuracy in blood analysis fuels the need for innovative reagent formulations that enhance test performance. Furthermore, reagents are cost-effective, making them widely accessible and contributing to their dominant market share.
Instruments are expected to grow at the fastest CAGR of 10.8% over the forecast period, owing to technological advancements and increasing demand for effective diagnostic solutions. In addition, modern blood screening instruments are designed to improve accuracy and efficiency, catering to the need for rapid diagnostics in healthcare settings. Furthermore, innovations such as high-throughput analyzers and point-of-care testing devices enhance the user experience and accessibility of blood testing. Despite challenges such as high costs and the reusable nature of some devices, ongoing technological developments are expected to drive long-term growth in this segment as healthcare providers seek reliable and efficient tools for blood analysis.
North America blood screening market dominated the global market and accounted for the largest revenue share of 38.4% in 2024 attributed to advanced healthcare infrastructure and a strong emphasis on patient safety. The region’s healthcare facilities have cutting-edge technology, ensuring accurate and efficient blood testing processes. In addition, there is a growing awareness of the importance of early disease detection, prompting healthcare providers to prioritize regular blood screenings. Furthermore, collaborative efforts between public health organizations and private sectors further enhance the accessibility and quality of blood screening services, fostering sustained market growth.
U.S. Blood Screening Market Trends
The U.S.blood screening market in thedominated the North American market and accounted for the largest revenue share in 2024, owing to a high number of blood donations and a robust regulatory framework. The country places great importance on ensuring the safety of blood transfusions, which drives the demand for comprehensive screening methods. In addition, technological advancements in testing procedures also contribute to this growth, improving accuracy and reducing turnaround times. Furthermore, favorable reimbursement policies encourage healthcare providers to adopt innovative blood screening technologies, enhancing overall public health outcomes.
Asia Pacific Blood Screening Market Trends
Asia Pacific blood screening market is expected to grow at a CAGR of 13.7% over the forecast period attributed to increasing healthcare awareness and economic development. Countries in this region are investing heavily in healthcare infrastructure, which enhances access to blood screening services. In addition, the rising prevalence of infectious diseases has heightened the need for effective screening processes. Furthermore, government initiatives aimed at promoting preventive healthcare are also driving demand for blood screening, positioning Asia Pacific as a key player in the global market with significant potential for innovation and expansion.
The blood screening market in Japan is expected to grow significantly over the forecast period, owing to its advanced technological landscape and a strong commitment to preventive health measures. In addition, the population is increasingly aware of the importance of regular health check-ups and blood safety. As the aging demographic grows, there is a heightened demand for diagnostic services to manage chronic diseases effectively. Furthermore, the Japanese government supports initiatives that improve blood donation rates and enhance screening technologies, ensuring that the country maintains high standards in blood safety practices.
Europe Blood Screening Market Trends
The Europe blood screening market is expected to grow substantially, driven by stringent regulatory standards and a focus on patient safety. Countries across the region have established comprehensive blood testing frameworks prioritizing quality assurance and risk management. In addition, the increasing incidence of infectious diseases drives demand for effective screening methods. Furthermore, collaborative efforts among public health organizations and private entities further enhance access to advanced blood screening technologies throughout Europe, promoting overall public health.
Germany Blood Screening Market Trends
The growth of the blood screening market in Germany is fueled by a strong emphasis on innovation and quality assurance within its healthcare system. The country prioritizes patient safety through rigorous testing protocols that ensure reliable results. In addition, growing awareness about blood-borne diseases drives demand for effective screening methods among healthcare providers. Furthermore, government initiatives promote regular health check-ups among citizens, while Germany's robust research environment fosters advancements in diagnostic technologies, ensuring that its blood screening practices remain efficient and effective in addressing public health needs.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the blood screening market
Technology
Product
Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers